Cite
HARVARD Citation
Fennell, D. et al. (2022). Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial. Lancet oncology. 23 (3), pp. 374-381. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Fennell, D. et al. (2022). Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial. Lancet oncology. 23 (3), pp. 374-381. [Online].